Timothy R. Wright
Chief Executive Officer

Mr. Wright was appointed Chief Executive Officer effective May 13, 2019. Previously, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011. Mr. Wright served as President and Chief Executive Officer of M2Gen Corp., a privately held cancer and health informatics company, between July 2017 and September 2018. Prior to M2Gen Corp., Mr. Wright served as Executive Vice President, Mergers and Acquisitions, Strategy and Innovation for Teva Pharmaceutical Industries Ltd., a pharmaceutical company specializing in generic medicines, from April 2015 until August 2017. Prior to that, Mr. Wright was the founding partner of The Ohio State University Comprehensive Cancer Drug Development Institute. Mr. Wright also served as Chairman, Interim Chief Executive Officer and a director of Curaxis Pharmaceutical Corporation, a pharmaceutical company specializing in the development of drugs for the treatment of Alzheimer’s disease and various cancers, from July 2011 to July 2012.

Mr. Wright has been a director of Agenus, Inc. (Nasdaq: AGEN), an immune oncology company, since 2006 and its lead director since 2009. Mr. Wright also serves as Chairperson of The Ohio State University Comprehensive Cancer Center Drug Development Institute, serves as Director of The Ohio State Innovation Foundation and sits on The Ohio State University College of Pharmacy Dean’s Corporate Council. Mr. Wright earned a Bachelor’s of Science in Marketing from The Ohio State University.

Peter M. Carlson
Executive Vice President, Chief Financial Officer

Peter M. Carlson was appointed Chief Financial Officer in March 2020, after joining MiMedx in December 2019 as Executive Vice President of Finance.

Previously, Mr. Carlson served as Chief Operating Officer at Brighthouse Financial, Inc., where he helped establish the $200 billion (assets) U.S. life and annuity insurance company as a separate entity following its August 2017 spin-off from MetLife, Inc. He was the Chief Accounting Officer at MetLife, Inc. for eight years where his global responsibilities included accounting, financial planning, tax, and investment finance. Prior to joining MetLife in 2009, Carlson was the Corporate Controller at Wachovia Corporation.

He currently serves as a director of White Mountains Insurance Company (NYSE: WTM). Mr. Carlson holds a Bachelor of Science from Wake Forest University and is a trustee of the university. He is licensed as a certified public accountant in North Carolina and New York.

William F. “Butch” Hulse
Executive Vice President, General Counsel

Mr. Hulse joined MiMedx in December 2019, and brings to MiMedx more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.

Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.

Rohit Kashyap, Ph.D.
Executive Vice President, Chief Commercial Officer
Rohit Kashyap, Ph.D., joined the Company as Executive Vice President and Chief Commercial Officer in August 2020. Dr. Kashyap has more than 20 years in the medical device sector. Most recently, he served as the President of Global Commercial at Acelity, L.P. Inc. (formerly known as Kinetic Concepts, Inc.) since April 2019. Prior thereto, Dr. Kashyap was the President of Americas, since January 2017, and President of North America, since October 2014. In these roles he led the company’s growth objectives by expanding core market leadership, identifying and developing new high-growth markets, and enhancing the overall product portfolio through the integration of additional businesses. Prior to that, Dr. Kashyap served as Senior Vice President of Strategy and Business Development at Acelity, Inc. from 2012 to 2014, and as Senior Vice President of Corporate Development from 2007 to 2010, with responsibility for the development of global strategic planning initiatives that incorporated organic growth, licensing, and strategic acquisitions. Since joining the company in 1998, Dr. Kashyap contributed in various roles within the R&D, Licensing and Acquisition, and Global Marketing groups, including as Commercial Leader for international and emerging markets. Dr. Kashyap earned his bachelor’s degree in Instrumentation and Control from the L.D. College of Engineering in Ahmedabad, India, and his master’s degree and doctorate in Biomedical Engineering from Case Western Reserve University. He also completed his MBA from the Kellogg School of Management at Northwestern University.
Robert B. Stein, M.D., Ph.D.
Executive Vice President, Research and Development

Dr. Robert B. Stein, M.D., Ph.D. joined MiMedx in August 2020 as Executive Vice President, Research and Development. After completing his Bachelors of Science with honors, earning a double major in both biology and chemistry at Indiana University, Dr. Stein received his M.D. and Ph.D. in Physiology and Pharmacology and completed his internship, residency and Board Certification in Anatomic and Clinical Pathology, all at Duke University. Following residency, Dr. Stein worked at Merck, with contributions to Cozaar, Sustiva, and Gardasil. He was then recruited as the first head of Research and Development for Ligand Pharmaceuticals, with responsibility for building the Research and Development organization and programs targeting various nuclear hormone receptors. This work led to eight pharmaceutical partnerships and six marketed medicines, including two SERMs (Fablyn and Viviant), three novel retinoids (Panretin, Targetin gel and capsules), and Promacta, the small molecule Thrombopoietin mimetic.

After six years at Ligand, he became Executive Vice President, Research and Pre-clinical Development for DuPont-Merck and DuPont pharmaceuticals, leading to the registration of Sustiva and Innohep and the discovery and advancement of blockbuster Eliquis, subsequently registered by Bristol Myers Squibb Company. Following the acquisition of DuPont by Bristol Myers Squibb, Dr. Stein joined Incyte Pharmaceuticals as President, R&D and Chief Scientific Officer, spearheading the transition from genomics to drug discovery and development. Following Incyte, Dr. Stein became President of Roche Palo Alto LLC, where he built Roche’s Translational Medicine capabilities, served on the Global Early Development Committee, Global Biologics Steering Committee, and Joint Roche-Genentech Steering Committee. Dr. Stein then joined Kinemed, a translational medicine company as Chief Executive Officer.

Following Kinemed, Dr. Stein served as President, R&D, for Agenus, an immuno-oncology company, with responsibility for the development of their R&D organization, and the advancement of four checkpoint modulatory antibodies and a personalized neo-epitope-directed cancer vaccine to Phase 1 trials. He also led the generation of a best-in-class TCR discovery and optimization effort. He served as a full time Senior Advisor, R&D, to Agenus and AgenTus from March 2017 to October 2019. During this time, Agenus advanced 13 monoclonal antibodies into the clinic and formed significant partnerships with Incyte, Merck, UCB, and Gilead. The two most advanced Agenus products, AGEN2034 (PD-1 antagonist monoclonal antibody) and AGEN1884 (CTLA-4 antagonist monoclonal antibody) are on track for potential BLA submission in 2020.

Dr. Stein is deeply experienced in the lab, including in the areas of molecular and cellular biology, biochemistry, enzymology, animal pharmacology, virology, drug metabolism, and safety assessment. He also has extensive experience in Translational Medicine and Early Clinical Development. He has led groups of over 1,000 scientists and physicians for over 15 years, supervising work in all the major therapeutic areas. In addition, Dr. Stein serves on the board of directors for a number of private and public company boards, and acts as an advisor to a multiple clients and academic institutions.

Mark P. Graves
Senior Vice President, Chief Compliance Officer

Mr. Graves joined MiMedx in July 2018 and brings more than 20 years of pharmaceutical and biotech industry experience to the Company, ranging from compliance and sales management to government affairs. He most recently was the U.S. leader for the global Patient Experience & Value function in the neurology division of UCB, Inc., a biopharmaceutical company. From 2011 to 2015, he was UCB’s Deputy Compliance Officer involved in all aspects of compliance including the implementation and management of the company’s corporate integrity agreement. Prior to that, Graves was Senior Director in the Office of Ethics and Compliance for the Pharmaceutical Products Division of Abbott Laboratories, as well as Deputy Ethics & Compliance Officer for Takeda Pharmaceuticals North America, Inc. and TAP Pharmaceutical Products, Inc. Prior to his pharmaceutical and biotech career, he practiced labor and employment law.

Mr. Graves holds a B.A. in Criminology and Law, and a J.D. from the University of Florida as well as an MBA from the University of Chicago Booth School of Business.

Stan Micek
Senior Vice President, Business Development and Portfolio Management

Stan Micek joined MiMedx in December, 2019. Prior to joining the Company, Mr. Micek served as the Vice President and Chief Commercial Officer for M2Gen, Corp. where he was responsible for all commercialization activities of the company including business development, strategic alliances, field sales and corporate communications.

From 2014 to 2018, Mr. Micek served as the Director, Oncology Commercialization at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) and Director of Licensing for The Ohio State University’s (OSU) Technology Commercialization Office. Prior to joining OSU, he held executive roles within two mid-sized pharmaceutical companies leading their corporate and business development functions, specifically in- and out-licensing, acquisitions, and divestitures. Mr. Micek also brings nineteen years of experience from Abbott Laboratories, where he held positions of increasing responsibility in several functional areas, including national account sales, marketing, business development and licensing, engineering and international manufacturing/ operations.

Mr. Micek earned his BS in Chemical Engineering from the Illinois Institute of Technology in Chicago and his MBA in Marketing and International Management from Northwestern University’s Kellogg Graduate School of Management in Evanston, IL.

Marion Snyder
Chief of Staff, Senior Vice President, Government Affairs

Marion Snyder was appointed Chief of Staff, Senior Vice President, Government Affairs in August 2021. Ms. Snyder joined MIMEDX in 2013, and throughout her tenure has continued to take on roles of increasing responsibility, most recently serving as Senior Vice President, Market Access, leading the Company’s Reimbursement, National Accounts, Health Policy, and Government Affairs efforts. Prior to joining MIMEDX, Ms. Snyder spent 13 years with Pfizer in a variety of roles, including Director of Payor Marketing for Enbrel, and started her career in sales and sales management with Johnson & Johnson.

Ms. Snyder earned her Bachelor of Science degree in Business Administration with a concentration in Marketing at Delaware Valley University.

Dirk Stevens, Ph.D.
Senior Vice President, Quality Assurance and Regulatory Affairs
Dirk Stevens, Ph.D. joined MiMedx in 2021 as Senior Vice President, Quality Assurance and Regulatory Affairs. Prior to joining MiMedx, Dr. Stevens, Ph.D. served as Vice President, Global Regulatory Affairs at Smith & Nephew, plc, since April 2019. During his time at Smith & Nephew, Dr. Stevens developed the company’s organizational regulatory strategy, and worked closely with Wound Management Regulatory on Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Prior to that, Dr. Stevens led Quality Systems and Regulatory Affairs for Fresenius Medical Care, beginning in May 2014. In both roles, he was responsible for developing strategic processes for deliverables management and measurement within regulatory affairs systems. Dr. Stevens has served as a quality and regulatory leader in the medical device and pharmaceutical industries, holding jobs of increasing responsibility at companies such as Johnson & Johnson, Baxter Healthcare, and Covidien. In addition, he was an officer in the U.S. Army, spending 5 years in active military service and another 10 years as a Reservist. Dr. Stevens earned his associate of arts, engineering at New Mexico Military Institute before going on to receive his bachelor of science in civil engineering at the United States Military Academy, West Point, NY. He continued his education at Keller Graduate School of Management, where he received his master’s in business administration before earning his Ph.D. at Walden University.
Scott Turner
Senior Vice President, Operations and Procurement

Scott Turner, has served as Senior Vice President, Operations and Procurement since April 2017. Mr. Turner oversees supply chain operations including donor recovery services, planning, procurement, processing, and facilities. Mr. Turner joined the Company in April 2016 as Vice President, Procurement. Prior to joining MiMedx, Mr. Turner served as a Director with Alvarez & Marsal, North America, LLC, in their Corporate Performance Improvement group from October 2015 until March 2016. Prior thereto, Mr. Turner served as Vice President, Supply Chain, with Larson-Juhl, a Berkshire Hathaway company, from June 2013 until September 2015. Additionally, Mr. Turner has more than 20 years of Supply Chain and Procurement leadership in life sciences at Shionogi and Johnson & Johnson, spanning the consumer, medical device, and pharmaceutical sectors domestically and internationally. Mr. Turner holds a Bachelor of Science in Commerce & Engineering from Drexel University and a President / Key Executives MBA from Pepperdine University.